Sohrevardi Seyed Mojtaba, Nasab Fatemeh Shojaei, Mirjalili Mohammad Reza, Bagherniya Mohammad, Tafti Arefeh Dehghani, Jarrahzadeh Mohammad Hossein, Azarpazhooh Mahmoud Reza, Saeidmanesh Mohsen, Banach Maciej, Jamialahmadi Tannaz, Sahebkar Amirhossein
Department of Clinical Pharmacy, Faculty of Pharmacy, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Stroke Prevention & Atherosclerosis Research Centre, University of Western Ontario, Canada.
Arch Med Sci. 2019 Nov 12;17(5):1423-1428. doi: 10.5114/aoms.2019.89330. eCollection 2021.
Delirium is one of the most prevalent complications in intensive care unit (ICU) patients, which is related to worse clinical outcomes including a longer ICU stay, longer duration of mechanical ventilation, higher mortality rates and increased risk of cognitive impairment. Observational studies have suggested that statins might have a positive effect on delirium status of hospitalized patients. To date, there has been no trial assessing the effect of atorvastatin on delirium status in critically ill patients. Thus, the aim of the current study was to determine the efficacy of atorvastatin on delirium status of patients in the ICU.
In this randomized, double-blind and controlled trial, a total of 90 patients in the general ICU who had delirium for at least 2 days were randomly divided into atorvastatin (40 mg/day) ( = 40) and control ( = 50) groups. Delirium status of the patients was determined twice a day at 10:00 a.m. and 18:00 p.m. using the Richmond Agitation-Sedation Scale (RASS).
Administration 40 mg/day of atorvastatin significantly reduced the mean RASS score and increased delirium-free days at both morning and afternoon time points compared to the control group ( < 0.05).
Administration of atorvastatin had a significant positive effect on delirium status in patients admitted to the ICU.
谵妄是重症监护病房（ICU）患者中最常见的并发症之一，它与更差的临床结局相关，包括更长的ICU住院时间、更长的机械通气时间、更高的死亡率以及认知障碍风险增加。观察性研究表明，他汀类药物可能对住院患者的谵妄状态有积极影响。迄今为止，尚无试验评估阿托伐他汀对危重症患者谵妄状态的影响。因此，本研究的目的是确定阿托伐他汀对ICU患者谵妄状态的疗效。
在这项随机、双盲和对照试验中，共有90名在普通ICU中谵妄至少2天的患者被随机分为阿托伐他汀组（40毫克/天）（n = 40）和对照组（n = 50）。使用里士满躁动镇静量表（RASS），于每天上午10:00和下午18:00对患者的谵妄状态进行两次评估。
与对照组相比，每天服用40毫克阿托伐他汀在上午和下午两个时间点均显著降低了平均RASS评分，并增加了无谵妄天数（P < 0.05）。
给予阿托伐他汀对入住ICU的患者的谵妄状态有显著的积极影响。
